The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Open accessAbstract
We show that DNA methyltransferase inhibitors (DNMTis) upregulate immune signaling in cancer through the viral defense pathway. In ovarian cancer (OC), DNMTis trigger cytosolic sensing of double-stranded RNA (dsRNA) causing a type I interferon response and apoptosis. Knocking down dsRNA sensors TLR3 and MAVS reduces this response 2-fold and blocking interferon beta or its receptor abrogates it. Upregulation of hypermethylated endogenous retrovirus (ERV) genes accompanies the response and ERV overexpression activates the response. Basal levels of ERV and viral defense gene expression significantly correlate in primary OC and the latter signature separates primary samples for multiple tumor types from The Cancer Genome Atlas into low versus high expression groups. In melanoma patients treated with an immune checkpoint therapy, high viral defense signature expression in tumors significantly associates with durable clinical response and DNMTi treatment sensitizes to anti-CTLA4 therapy in a pre-clinical melanoma model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The IFN-I response could also expose the tumor cells to surveillance by the immune system96, 97.”
From The role of retrotransposable elements in ageing and age-associated diseases (2021) · cites this paper as [97]
The cited source says what the claim attributes to it.
In the citing paper
“multiple studies have shown that DNA demethylating agents among other epigenetic modulators can induce a type I IFN response in cancer cells through the de-repression of endogenous retroviruses (ERVs) and activation of the MDA5-MAVS pathway38–40.”
From Epigenetic state determines the in vivo efficacy of STING agonist therapy (2023) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“DAC treatment could induce expression of retrotransposons normally silenced by DNA methylation, which could also augment tumor immunogenicity10–14,99.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [12]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“inactivated typical enhancers were associated with collagen fibril organization and chemotaxis GO terms and were enriched for binding motifs of immune-related TFs, including STAT1 (Fig. 2a, b)12,13.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“inhibiting EZH2 activity can either positively or negatively influence tumour-specific immune responses by modulating both tumour immunogenicity and the function of infiltrating T-cells, NK-cells and macrophages 196 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [196]
In the citing paper
“derepression of endogenous retroviral elements coupled to robust type I and type III IFN signaling”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chiappinelli et al., 2015
In the citing paper
“Certainly, this dual epigenetic targeting may influence additional antiproliferative mechanisms and further enhance antitumor surveillance by the immune system (Chiappinelli et al., 2015).”
From HDACs and the epigenetic plasticity of cancer cells: target the complexity (2022) · cites this paper as Chiappinelli et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Wilkerson, M. D., & Hayes, D. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq170 · Cited by 5,645
Cited by
Sorted by citations
Items 301–400 of 1,003
Chemotherapy-induced transposable elements activate MDA5 to enhance haematopoietic regeneration
Clapes, T., Polyzou, A., Prater, P., Sagar, Morales‐Hernández, A., Ferrarini, M. G., Kehrer, N., Lefkopoulos, S., Bergo, V., Hummel, B., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00707-9 · Cited by 89
Wu, S.-Y., Xiao, Y., Wei, J., Xu, X., Jin, X., Hu, X., Li, D., Jiang, Y., & Shao, Z.-M. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002528 · Cited by 93
Epigenetic regulation in cancer therapy: From mechanisms to clinical advances
Tao, L., Zhou, Y., Luo, Y., Qiu, J., Xiao, Y., Zou, J., Zhang, Y., Liu, X., Yang, X., Gou, K., et al. (2024) · MedComm – Oncology · doi:10.1002/mog2.59 · Cited by 95
Göke, J., & Ng, H. (2016) · EMBO Reports · doi:10.15252/embr.201642743 · Cited by 93
DNA methylation dynamics at transposable elements in mammals
Jansz, N. (2019) · Essays in Biochemistry · doi:10.1042/ebc20190039 · Cited by 95
A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy
Liu, Z., Ren, Y., Weng, S., Xu, H., Li, L., & Han, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.809761 · Cited by 92
The competitive landscape of the dsRNA world
Cottrell, K. A., Andrews, R. J., & Bass, B. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.11.033 · Cited by 88
Adapting Cancer Immunotherapy Models for the Real World
Klevorn, L. E., & Teague, R. M. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.03.010 · Cited by 88
Loss of pyruvate kinase M2 limits growth and triggers innate immune signaling in endothelial cells
Stone, O. A., El-Brolosy, M. A., Wilhelm, K., Liu, X., Romão, A. M., Grillo, E., Lai, J. K. H., Günther, S., Jeratsch, S., Kuenne, C. T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06406-8 · Cited by 91
Human endogenous retroviruses role in cancer cell stemness
Matteucci, C., Balestrieri, E., Argaw-Denboba, A., & Vallebona, P. S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.10.001 · Cited by 88
The Roles of DNA Methylation in the Stages of Cancer
McMahon, K. W., Karunasena, E., & Ahuja, N. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000279 · Cited by 88
Gillberg, L., Ørskov, A. D., Nasif, A., Ohtani, H., Madaj, Z., Hansen, J. W., Rapin, N., Mogensen, J. B., Liu, M., Dufva, I. H., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0739-5 · Cited by 91
Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition
Kim, H. J., Cantor, H., & Cosmopoulos, K. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.08.010 · Cited by 88
Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
Bewersdorf, J. P., Shallis, R. M., Stahl, M. F., & Zeidan, A. M. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620718816698 · Cited by 88
Turelli, P., Playfoot, C. J., Grun, D., Raclot, C., Pontis, J., Coudray, A., Thorball, C. W., Duc, J., Pankevich, E. V., Deplancke, B., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba3200 · Cited by 85
Type I interferons and related pathways in cell senescence
Frisch, S. M., & MacFawn, I. (2020) · Aging Cell · doi:10.1111/acel.13234 · Cited by 89
Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation
Zahnow, C. A., Topper, M. J., Stone, M. L., Stewart, T. M., Li, H., Baylin, S. B., & Casero, R. A. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.01.007 · Cited by 88
Self-citationEmerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming
Torrano, J., Emran, A. A., Hammerlindl, H., & Schaider, H. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0644-y · Cited by 87
Human Endogenous Retrovirus K in Cancer: A Potential Biomarker and Immunotherapeutic Target
Curty, G., Marston, J. L., Rougvie, M. D. M., Leal, F. E., Nixon, D. F., & Soares, M. A. (2020) · Viruses · doi:10.3390/v12070726 · Cited by 84
Ovarian cancer: epigenetics, drug resistance, and progression
Xie, W., Sun, H., Li, X., Lin, F., Wang, Z., & Wang, X. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02136-y · Cited by 90
Flanagan, J. M., Wilson, A. M., Koo, C., Masrour, N., Gallon, J., Loomis, E. W., Flower, K. J., Wilhelm-Benartzi, C. S., Hergovich, A., Cunnea, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1754 · Cited by 82
Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial
Giacomo, A. M. D., Covre, A., Finotello, F., Rieder, D., Danielli, R., Sigalotti, L., Giannarelli, D., Petitprez, F., Lacroix, L., Valente, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1335 · Cited by 83
Lefkopoulos, S., Polyzou, A., Derecka, M., Bergo, V., Clapes, T., Cauchy, P., Jerez‐Longres, C., Onishi‐Seebacher, M., Yin, N., Calderón, N. M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.10.007 · Cited by 85
Burbage, M., Rocañín-Arjó, A., Baudon, B., Arribas, Y. A., Merlotti, A., Rookhuizen, D. C., Heurtebise-Chrétien, S., Ye, M., Houy, A., Burgdorf, N., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.abm6360 · Cited by 86
Role of Transposable Elements in Genome Stability: Implications for Health and Disease
Bhat, A., Ghatage, T., Bhan, S., Lahane, G. P., Dhar, A., Kumar, R., PANDITA, R. K., Bhat, K. M., Ramos, K. S., & Pandita, T. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147802 · Cited by 82
Epigenomic heterogeneity as a source of tumour evolution
Laisné, M., Lupien, M., & Vallot, C. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00757-9 · Cited by 93
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
Xiao, Q., Nobre, A., Piñeiro, P., Berciano‐Guerrero, M., Alba, E., Cobo, M., Lauschke, V. M., & Barragán, I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010286 · Cited by 82
Ren, J., Li, N., Pei, S., Lian, Y., Li, L., Peng, Y., Liu, Q., Guo, J., Wang, X., Han, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153167 · Cited by 85
Mammalian genome innovation through transposon domestication
Modzelewski, A. J., Chong, J. G., Wang, T., & He, L. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00970-4 · Cited by 88
DNA Methylation: From Cancer Biology to Clinical Perspectives
Chen, C., Wang, Z., Ding, Y., Wang, L., Wang, S., Wang, H., & Qin, Y. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2712326 · Cited by 89
Wolff, F., Leisch, M., Greil, R., Risch, A., & Pleyer, L. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0168-z · Cited by 85
Chen, J., Foroozesh, M. K., & Qin, Z. (2019) · Oncogenesis · doi:10.1038/s41389-018-0114-y · Cited by 79
OAS-RNase L innate immune pathway mediates the cytotoxicity of a DNA-demethylating drug
Banerjee, S., Gusho, E., Gaughan, C., Dong, B., Gu, X., Holvey-Bates, E. G., Talukdar, M., Li, Y., Weiss, S. R., Sicheri, F., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815071116 · Cited by 79
Ishiguro, K., Kitajima, H., Niinuma, T., Maruyama, R., Nishiyama, N., Ohtani, H., Sudo, G., Toyota, M., Sasaki, H., Yamamoto, E., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-020-00400-0 · Cited by 79
Endogenous Double-Stranded RNA
Sadeq, S., Al-Hashimi, S., Cusack, C. M., & Werner, A. (2021) · Non-Coding RNA · doi:10.3390/ncrna7010015 · Cited by 81
The Immunological Conundrum of Endogenous Retroelements
Kassiotis, G. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-033341 · Cited by 81
Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors
Daskalakis, M., Brocks, D., Sheng, Y.-H., Islam, S., Ressnerova, A., Assenov, Y., Milde, T., Oehme, I., Witt, O., Goyal, A., et al. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1442623 · Cited by 90
Chromatin dependencies in cancer and inflammation
Marazzi, I., Greenbaum, B. D., Low, D. H. P., & Guccione, E. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.113 · Cited by 80
DNA Methyltransferase 1 Controls Nephron Progenitor Cell Renewal and Differentiation
Wanner, N., Vornweg, J., Combes, A. N., Wilson, S. B., Plappert, J., Rafflenbeul, G., Puelles, V. G., Rahman, R., Liwinski, T., Lindner, S., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018070736 · Cited by 79
Expressional activation and functional roles of human endogenous retroviruses in cancers
Zhang, M., Liang, Q., & Zheng, S. S. (2019) · Reviews in Medical Virology · doi:10.1002/rmv.2025 · Cited by 79
DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses
Dan, H., Zhang, S., Zhou, Y., & Guan, Q. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s217767 · Cited by 83
The Emerging Role of Long Non-Coding RNAs in the Metastasis of Hepatocellular Carcinoma
Chen, X., Tang, F. R., Arfuso, F., Cai, W.-Q., Ma, Z., Yang, J., & Sethi, G. (2019) · Biomolecules · doi:10.3390/biom10010066 · Cited by 79
Khan, A. A., Liu, X., Yan, X., Tahir, M., Ali, S., & Huang, H. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09952-0 · Cited by 78
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
Goswami, M., Gui, G., Dillon, L. W., Lindblad, K. E., Thompson, J., Valdez, J., Kim, D., Ghannam, J. Y., Oetjen, K. A., DeStefano, C. B., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003392 · Cited by 84
Endogenous Retroviruses: With Us and against Us
Meyer, T. J., Rosenkrantz, J. L., Carbone, L., & Chavez, S. L. (2017) · Frontiers in Chemistry · doi:10.3389/fchem.2017.00023 · Cited by 81
Kuss-Duerkop, S. K., Westrich, J. A., & Pyeon, D. (2018) · Viruses · doi:10.3390/v10020082 · Cited by 80
Deregulation of Retroelements as an Emerging Therapeutic Opportunity in Cancer
Ishak, C. A., Classon, M., & Carvalho, D. D. D. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.05.008 · Cited by 79
Heidari, A. (2016) · Translational Biomedicine · doi:10.21767/2172-0479.100076 · Cited by 78
Holderried, T. A. W., de Vos, L., Bawden, E., Vogt, T. J., Dietrich, J., Zarbl, R., Bootz, F., Kristiansen, G., Brossart, P., Landsberg, J., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0752-8 · Cited by 79
Human endogenous retroviruses in development and disease
Mao, J., Zhang, Q., & Cong, Y. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.10.037 · Cited by 77
Exosome regulation of immune response mechanism: Pros and cons in immunotherapy
Essola, J. M., Zhang, M., Yang, H., Li, F., Xia, B., Mavoungou, J. F., Hussain, A., & Huang, Y. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.09.018 · Cited by 82
PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survival
Micevic, G., Thakral, D., McGeary, M. K., & Bosenberg, M. (2018) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12745 · Cited by 79
Novel Strategies for Cancer Treatment: Highlights from the 55th IACR Annual Conference
Charmsaz, S., Collins, D. M., Perry, A. S., & Prencipe, M. (2019) · Cancers · doi:10.3390/cancers11081125 · Cited by 77
Fresquet, V., Garcia-Barchino, M. J., Larráyoz, M., Celay, J., Vicente, C., Fernández‐Galilea, M., Larráyoz, M. J., Calasanz, M. J., Panizo, C., Junza, A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1065 · Cited by 77
Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer
Chen, S., Xie, P., Cowan, M. L., Huang, H., Cárdenas, H., Keathley, R., Tanner, E. J., Fleming, G. F., Moroney, J. W., Pant, A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158800 · Cited by 78
Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
Gstalder, C., Liu, D., Miao, D., Lutterbach, B. A., DeVine, A. L., Lin, C., Shettigar, M., Pancholi, P., Buchbinder, E. I., Carter, S. L., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1416 · Cited by 75
D’Anna, F., Dyck, L. V., Xiong, J., Zhao, H., Berrens, R. V., Qian, J., Bieniasz-Krzywiec, P., Chandra, V., Schoonjans, L., Matthews, J. B., et al. (2020) · Genome biology · doi:10.1186/s13059-020-02087-z · Cited by 76
Kreidieh, F., Dalle, I. A., Moukalled, N. M., Cheikh, J. E., Brissot, É., Mohty, M., & Bazarbachi, A. A. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03416-7 · Cited by 76
Du, B., & Waxman, D. J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.11.025 · Cited by 76
Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment
Pan, X., & Zheng, L. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0505-9 · Cited by 79
WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway
Guo, E., Xiao, R., Wu, Y., Lu, F., Liu, C., Yang, B., Li, X., Fu, Y., Wang, Z., Yuan, L., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210789 · Cited by 74
Kuang, C., Park, Y., Augustin, R. C., Lin, Y., Hartman, D. J., Seigh, L., Pai, R. K., Sun, W., Bahary, N., Ohr, J. P., et al. (2022) · Clinical Epigenetics · doi:10.1186/s13148-021-01226-y · Cited by 75
DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma
Zhang, L., Li, H., Shereda, R., Lu, Q., Weisenberger, D. J., O'Connell, C. L., Machida, K., An, W., Lenz, H., El-Khoueiry, A. B., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215899 · Cited by 79
Self-citationMaking a virtue of necessity: the pleiotropic role of human endogenous retroviruses in cancer
Kassiotis, G., & Stoye, J. P. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0277 · Cited by 78
Colorectal cancer: epigenetic alterations and their clinical implications
Puccini, A., Berger, M. D., Naseem, M., Tokunaga, R., Battaglin, F., Cao, S., Hanna, D. L., McSkane, M., Soni, S., Zhang, W., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.09.003 · Cited by 76
TCR-engineered T cells to treat tumors: Seeing but not touching?
Debets, R., Donnadieu, E., Chouaı̈b, S., & Coukos, G. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.002 · Cited by 73
de Cubas, A. A., Dunker, W., Zaninovich, A., Hongo, R. A., Bhatia, A., Panda, A., Beckermann, K. E., Bhanot, G., Ganesan, S., Karijolich, J. J., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.137569 · Cited by 81
Dhillon, P., Mulholland, K. A., Hu, H., Park, J., Sheng, X., Abedini, A., Liu, H., Vassalotti, A., Wu, J., & Suszták, K. (2023) · Nature Communications · doi:10.1038/s41467-023-36212-w · Cited by 74
Lucarini, V., Buccione, C., Ziccheddu, G., Peschiaroli, F., Sestili, P., Puglisi, R., Mattia, G., Zanetti, C., Parolini, I., Bracci, L., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.08.024 · Cited by 73
Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives
Schiffmann, I., Greve, G., Jung, M., & Lübbert, M. (2016) · Epigenetics · doi:10.1080/15592294.2016.1237345 · Cited by 75
Scheller, M., Ludwig, A. K., Göllner, S., Rohde, C., Krämer, S., Stäble, S., Janssen, M., Müller, J.-A., He, L., Bäumer, N., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00213-9 · Cited by 73
Emerging therapeutic targets for the treatment of malignant rhabdoid tumors
Nemes, K., & Frühwald, M. C. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1451839 · Cited by 74
Nahas, M. R., Stroopinsky, D., Rosenblatt, J. M., Cole, L., Pyzer, A. R., Anastasiadou, E., Сергеева, А., Ephraim, A., Washington, A. J., Orr, S., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15818 · Cited by 74
Rovatti, P. E., Gambacorta, V., Lorentino, F., Ciceri, F., & Vago, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00147 · Cited by 74
Differentiation therapy for myeloid malignancies: beyond cytotoxicity
Stubbins, R. J., & Karsan, A. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00584-3 · Cited by 75
Badal, B., Solovyov, A., Cecilia, S. D., Chan, J. M., Chang, L., Iqbal, R., Aydin, I. T., Rajan, G. S., Chen, C., Abbate, F., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92102 · Cited by 72
Kuendgen, A., Müller‐Thomas, C., Lauseker, M., Haferlach, T., Urbaniak, P., Schroeder, T. A., Brings, C., Wulfert, M., Meggendorfer, M., Hildebrandt, B., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25328 · Cited by 74
Yamashita, A. S., Rosa, M. D. C., Borodovsky, A., Festuccia, W. T., Chan, T. A.-T., & Riggins, G. J. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy146 · Cited by 73
Self-citationHardy, M., Audemard, E. O., Migneault, F., Feghaly, A., Brochu, S., Gendron, P., Boilard, É., Major, F., Dieudé, M., Hébert, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43591-y · Cited by 76
P53 and the defenses against genome instability caused by transposons and repetitive elements
Levine, A. J., Ting, D. T., & Greenbaum, B. D. (2016) · BioEssays · doi:10.1002/bies.201600031 · Cited by 73
Epigenetic Compensation Promotes Liver Regeneration
Wang, S., Zhang, C., Hasson, D., Desai, A., SenBanerjee, S., Magnani, E., Ukomadu, C., Lujambio, A., Bernstein, E., & Sadler, K. C. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.05.034 · Cited by 73
Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes
Matei, D. E., & Nephew, K. P. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3837 · Cited by 71
DNA methyltransferases in hematological malignancies
Hoang, N.-M., & Rui, L. (2020) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2020.04.006 · Cited by 76
TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia
Bensberg, M., Rundquist, O., Selimović-Pašić, A., Lagerwall, C., Benson, M., Gustafsson, M., Vogt, H., Lentini, A., & Nestor, C. E. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110758118 · Cited by 70
Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer
Huang, W., Zhu, Q., Shi, Z., Tu, Y., Li, Q., Zheng, W., Yuan, Z., Li, L., Zu, X., Hao, Y., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01895-7 · Cited by 81
Epigenetic Modifiers in Immunotherapy: a Focus on Checkpoint Inhibitors
Terranova-Barberio, M., Thomas, S., & Münster, P. N. (2016) · Immunotherapy · doi:10.2217/imt-2016-0014 · Cited by 71
Liu, M., Zhou, J., Chen, Z., & Cheng, A. S. L. (2016) · The Journal of Pathology · doi:10.1002/path.4832 · Cited by 69
Cell-Intrinsic Barriers of T Cell-Based Immunotherapy
Ghoneim, H. E., Zamora, A. E., Thomas, P. G., & Youngblood, B. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.10.002 · Cited by 71
Rath, S. P., Prangley, E., Donovan, J., Demarest, K., Wingreen, N. S., Meir, Y., & Korennykh, A. V. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.027 · Cited by 67
Sheng, W., Liu, Y., Chakraborty, D., Debo, B. M., & Shi, Y. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0017 · Cited by 71
PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade
Srour, N., Villarreal, O. D., Hardikar, S., Yu, Z., Preston, S. E. J., Miller, W. H., Szewczyk, M. M., Baršytė-Lovejoy, D., Xu, H., Chen, T., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110582 · Cited by 70
Endogenous Retroviruses as Modulators of Innate Immunity
Russ, E. U., & Iordanskiy, S. (2023) · Pathogens · doi:10.3390/pathogens12020162 · Cited by 74
Towards targeting transposable elements for cancer therapy
Liang, Y., Qu, X., Shah, N. M., & Wang, T. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-023-00653-8 · Cited by 79
Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine
Coyle, K. M., Boudreau, J. E., & Marcato, P. (2017) · BioMed Research International · doi:10.1155/2017/9620870 · Cited by 72
Taylor, K., Yau, H. L., Chakravarthy, A., Wang, B., Shen, S. Y., Ettayebi, I., Ishak, C. A., Bedard, P. L., Razak, A. A., Hansen, A. R., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000883 · Cited by 70
A Blueprint to Advance Colorectal Cancer Immunotherapies
Le, D. T., Hubbard-Lucey, V. M., Morse, M. A., Heery, C. R., Dwyer, A. J., Marsilje, T. H., Brodsky, A. N., Chan, E. W., Deming, D. A., Diaz, L. A., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0375 · Cited by 71
Dowless, M. S., Lowery, C. D., Shackleford, T. J., Renschler, M., Stephens, J., Flack, R. S., Blosser, W. D., Gupta, S., Stewart, J. A., Webster, Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1256 · Cited by 68
Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy
Ban, W., Guan, J., Huang, H., He, Z., Sun, M., Liu, F., & Sun, J. (2022) · Nano Research · doi:10.1007/s12274-021-4031-6 · Cited by 70
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Wang, S. L., & Chan, T. A.-T. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.006 · Cited by 80
Self-citationDNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension
Licht, J. D. (2015) · Cell · doi:10.1016/j.cell.2015.08.005 · Cited by 69
Metadata
- Authors
- Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., Makarov, V., Buhu, S., Slamon, D. J., Wolchok, J. D., Pardoll, D. M., Beckmann, M. W., Zahnow, C. A., Merghoub, T., Chan, T. A., Baylin, S. B., & Strick, R.
- Affiliations
- Johns Hopkins University (US)
- Universitätsklinikum Erlangen (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Case Western Reserve University (US)
- University of California, Los Angeles (US)
- Corresponding author
- Baylin, Stephen B.
- Strick, Reiner
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 162
- Issue
- 5
- Pages
- 974-986
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4556003
- OpenAlex
- W1953890763
- Cited by
- 2,022
- References
- 94
- Citations by year
- 2026: 193 · 2025: 188 · 2024: 211 · 2023: 209 · 2022: 225 · 2021: 250 · 2020: 184 · 2019: 163 · 2018: 161 · 2017: 133 · 2016: 93 · 2015: 10
- FWCI
- 65.10
- Type
- journal article
- Language
- en
- Update notices
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50CA058184, CA058184, F32CA183214, P30CA008748)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- hypomethylating agents, DNA methylation, type I interferon response, double-stranded RNA sensing, endogenous retroviruses, ovarian cancer, melanoma, TLR3, MAVS, interferon-beta, apoptosis, immune checkpoint therapy, CTLA-4, tumor immune microenvironment, epigenetic reprogramming
- MeSH terms
- Animals, Azacitidine, Female, Humans, Immunotherapy, Interferon Type I, Lung Neoplasms, Melanoma, Mice, Inbred C57BL, Ovarian Neoplasms, RNA, Double-Stranded, DNA Modification Methylases, DNA Methylation, Endogenous Retroviruses, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
